Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic|Communicable Diseases|Hepatitis C
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2011-000946-39 |
2011-000946-39 | P2 |
Completed |
Hepatitis C |
2018-04-09 |
2025-07-02 |
Treatments |
|
2011-000945-19 |
2011-000945-19 | P2 |
Terminated |
Hepatitis C |
2017-11-30 |
2025-06-18 |
Treatments |
|
NCT01805882 |
13-I-0066 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2015-08-01 |
2019-03-19 |
||
NCT02226549 |
GS-US-337-1512 | P2 |
Completed |
Hepatitis C|Communicable Diseases |
2015-02-01 |
2019-03-20 |
Treatments |
|
2010-023952-10 |
2010-023952-10 | P2 |
Terminated |
Hepatitis C, Chronic |
2013-08-15 |
2022-03-13 |
Treatments |
|
2011-002748-28 |
2011-002748-28 | P2 |
Completed |
Hepatitis C, Chronic |
2013-07-29 |
2022-03-13 |
Treatments |
|
2011-000456-42 |
2011-000456-42 | P2 |
Completed |
Hepatitis C |
2013-06-14 |
2022-03-13 |
Treatments |
|
NCT01384383 |
GS-US-248-0121 | P2 |
Terminated |
Hepatitis A|Hepatitis C, Chronic |
2013-06-01 |
2019-03-19 |
Treatments |
|
NCT01371578 |
Protocol GS US 256 0124 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-03-01 |
2019-03-19 |
Treatments |
|
NCT01271790 |
GS-US-196-0140 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-01-01 |
2019-03-19 |
||
NCT01435226 |
GS-US-248-0131 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-01-01 |
2019-03-19 |
Treatments |
|
NCT01434498 |
Protocol No. GS US 248 0132 | P2 |
Completed |
Communicable Diseases |
2013-01-01 |
2019-03-19 |
Treatments |
|
NCT01353248 |
GS-US-248-0120 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2012-10-01 |
2019-03-19 |
||
2011-000944-43 |
2011-000944-43 | P2 |
Completed |
Hepatitis C |
2012-07-14 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|